21 – 30 of 35
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Monoclonal Gammopathy of Undetermined Significance and Risk of Infections A Population Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
(
- Contribution to journal › Article
-
Mark
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
(
- Contribution to journal › Article
- 2009
-
Mark
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Risk of plasma cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden
(
- Contribution to journal › Article
-
Mark
Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
(
- Contribution to journal › Article
-
Mark
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
(
- Contribution to journal › Article
-
Mark
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
(
- Contribution to journal › Article